scholarly journals Impact of Early Antiretroviral Therapy on Detection of Cell-Associated HIV-1 Nucleic Acid in Blood by the Roche Cobas TaqMan Test

2019 ◽  
Vol 57 (5) ◽  
Author(s):  
Linda L. Jagodzinski ◽  
Mark M. Manak ◽  
Holly R. Hack ◽  
Ying Liu ◽  
Jennifer A. Malia ◽  
...  
Keyword(s):  
Nucleic Acid ◽  
Antiretroviral Therapy ◽  
Rapid Decline ◽  
Assay Sensitivity ◽  
Predictive Values ◽  
Cobas Taqman ◽  
Art Initiation ◽  
Limit Of Quantitation ◽  
Hiv 1 ◽  
Roche Cobas

ABSTRACTThe Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test, v2.0 (the CAP/CTM assay), was used to quantify cell-associated HIV-1 (CAH) nucleic acid in peripheral blood mononuclear cells (PBMC) from well-characterized clinical specimens from HIV-1-infected individuals on antiretroviral therapy (ART). Chronically infected individuals on ART with no detectable plasma HIV-1 RNA demonstrated average CAH burdens of 3.2 HIV-1 log10copies/million cells. Assay sensitivity and specificity were 98.9% and 100%, respectively, with the positive and negative predictive values being 100% and 98.6%, respectively. The CAH burden was also measured at weeks 0, 1, 2, 8, and 60 in 37 participants (RV254/SEARCH010, Bangkok, Thailand) stratified by Fiebig stage (Fiebig stage I [FI] to FVI) at ART initiation. Prior to ART initiation, the average CAH burden was 1.4, 4.1, and 3.6 log10copies/million PBMCs for individuals who initiated ART at FI, FII, and FIII to FVI, respectively. Initiation of ART resulted in a rapid decline of CAH in all individuals, with the greatest decrease being observed in individuals who initiated ART at FI to FIII. By week 60, 100% (FI), 71.8% (FII/FIII), and 20.5% (FIV to FVI) of samples from individuals initiating treatment were at or near the limit of quantitation. Residual CAH was detectable at 60 weeks in most individuals who initiated ART at later stages (FIV to FVI) and averaged 1.9 ± 0.7 log10copies/million PBMCs. The modified Roche CAP/CTM assay provides a convenient, standardized approach to measure residual HIV in blood and may be useful for monitoring patients under therapy or those participating in HIV remission studies.

scholarly journals A Simpler and More Sensitive Single-Copy HIV-1 RNA Assay for Quantification of Persistent HIV-1 Viremia in Individuals on Suppressive Antiretroviral Therapy

2019 ◽  
Vol 57 (3) ◽  
Author(s):  
Melissa A. Tosiano ◽  
Jana L. Jacobs ◽  
Kathleen A. Shutt ◽  
Joshua C. Cyktor ◽  
John W. Mellors
Keyword(s):  
Nucleic Acid ◽  
Antiretroviral Therapy ◽  
Limit Of Detection ◽  
Single Copy ◽  
Mean Value ◽  
Probit Analysis ◽  
Pcr Assay ◽  
Assay Sensitivity ◽  
The Impact ◽  
Hiv 1

ABSTRACTA real-time quantitative reverse transcriptase PCR assay with single-copy sensitivity targeting the integrase region of HIV-1 (integrase single-copy assay [iSCA] v1.0) has been widely used to quantify plasma viremia in individuals on antiretroviral therapy (ART). iSCA v1.0 requires the use of an ultracentrifuge, and only about half of the nucleic acid extracted from plasma is assayed for HIV-1 RNA. We sought to simplify sample processing using microcentrifugation and improve assay sensitivity by testing more than 75% of the total extracted nucleic acid for HIV-1 RNA (iSCA v2.0). We evaluated the limit of detection (LoD) of iSCA v2.0 by testing replicates of low-copy plasma HIV-1 RNA standards. By probit analysis, the 95% LoD was 1 copy of HIV-1 RNA per milliliter for a 5-ml plasma sample. To compare the sensitivity of iSCA v1.0 and v2.0, we tested plasma samples with both assays from 60 participants on ART with HIV-1 RNA below 20 cps/ml. Of the 31 samples that had no detectable HIV-1 RNA by iSCA v1.0, 17 (55%) were detectable by v2.0 with an HIV-1 RNA mean value of 3.5 cps/ml. Twenty-nine samples were detectable with both assay versions, but average values of HIV-1 RNA cps/ml were 2.7-fold higher for v2.0 than v1.0. These results support the adoption of a new, more sensitive and simpler single-copy HIV-1 RNA assay (iSCA v2.0) to quantify residual viremia on ART and to assess the impact of experimental interventions designed to decrease HIV-1 reservoirs.

Comparing Abbott m2000 RealTime HIV test and Roche COBAS Ampliprep/COBAS Taqman HIV test, v2.0 in treated HIV-1 B and non-B subjects with low viraemia

2015 ◽  
Vol 88 (4) ◽  
pp. 724-727 ◽  
Author(s):  
Apostolia Margariti ◽  
Dimitrios Chatzidimitriou ◽  
Simeon Metallidis ◽  
Dimitrios Pilalas ◽  
Andreas Kourelis ◽  
...  
Keyword(s):  
Cobas Taqman ◽  
Hiv Test ◽  
Hiv 1 ◽  
Roche Cobas

Comparison of HIV-1 Viral Load between Abbott m2000 and Roche COBAS TaqMan Methods

2010 ◽  
Vol 02 (03) ◽  
Author(s):  
Joseph Nkeze Dong Liang ◽  
Heather Adkins Richard Y. Zhao
Keyword(s):  
Viral Load ◽  
Cobas Taqman ◽  
Hiv 1 ◽  
Roche Cobas

scholarly journals Selective Decay of Intact HIV-1 Proviral DNA on Antiretroviral Therapy

2020 ◽  
Author(s):  
Rajesh T Gandhi ◽  
Joshua C Cyktor ◽  
Ronald J Bosch ◽  
Hanna Mar ◽  
Gregory M Laird ◽  
...  
Keyword(s):  
Antiretroviral Therapy ◽  
Half Life ◽  
Plasma Viremia ◽  
Art Initiation ◽  
Markers Of Inflammation ◽  
Infected Cells ◽  
Selective Decay ◽  
Hiv 1 ◽  
Over Time ◽  
Residual Plasma Viremia

Abstract Background HIV-1 proviruses persist in people on antiretroviral therapy (ART) but most are defective and do not constitute a replication-competent reservoir. The decay of infected cells carrying intact compared with defective HIV-1 proviruses has not been well defined in people on ART. Methods We separately quantified intact and defective proviruses, residual plasma viremia, and markers of inflammation and activation in people on long-term ART. Results Among 40 participants tested longitudinally from a median of 7.1 years to 12 years after ART initiation, intact provirus levels declined significantly over time (median half-life, 7.1 years; 95% confidence interval [CI], 3.9–18), whereas defective provirus levels did not decrease. The median half-life of total HIV-1 DNA was 41.6 years (95% CI, 13.6–75). The proportion of all proviruses that were intact diminished over time on ART, from about 10% at the first on-ART time point to about 5% at the last. Intact provirus levels on ART correlated with total HIV-1 DNA and residual plasma viremia, but there was no evidence for associations between intact provirus levels and inflammation or immune activation. Conclusions Cells containing intact, replication-competent proviruses are selectively lost during suppressive ART. Defining the mechanisms involved should inform strategies to accelerate HIV-1 reservoir depletion.

Comparison of the bioMérieux NucliSENS EasyQ HIV-1 v2.0–HIV-1 RNA quantification assay versus Abbott RealTime HIV-1 and Roche Cobas TaqMan HIV-1 v2.0 on current epidemic HIV-1 variants

2015 ◽  
Vol 71 ◽  
pp. 76-81 ◽  
Author(s):  
Thomas Mourez ◽  
Constance Delaugerre ◽  
Muriel Vray ◽  
Véronique Lemée ◽  
François Simon ◽  
...  
Keyword(s):  
Cobas Taqman ◽  
Rna Quantification ◽  
Hiv 1 ◽  
Roche Cobas

scholarly journals Comparison of the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 test v1.0 with v2.0 in HIV-1 viral load quantification

2015 ◽  
Vol 31 (4) ◽  
pp. 188-193 ◽  
Author(s):  
Yi-Ching Tung ◽  
Liang-Yin Ke ◽  
Po-Liang Lu ◽  
Kuei-Hsiang Lin ◽  
Su-Chen Lee ◽  
...  
Keyword(s):  
Viral Load ◽  
Cobas Taqman ◽  
Viral Load Quantification ◽  
Hiv 1 ◽  
Roche Cobas
Sign in / Sign up

Export Citation Format

Share Document